Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 501 Authors: Robert E. Coleman, Dianne Finkelstein,...
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 507 Authors: Valentina Guarneri, Maria Vittoria Dieci,...
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 506 Authors: Helena Margaret Earl, Louise Hiller,...
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
23 septembra, 2020 4:53 pm Leave your thoughtsJune 5, 2018 A 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months...
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: LBA1 Authors: Joseph A. Sparano, Robert James...
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy
23 septembra, 2020 4:53 pm Leave your thoughtsJune 4, 2018 Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive,...
KARCINOM PRSU NA ASCO 2018
23 septembra, 2020 4:53 pm Leave your thoughtsNejvětší novinky prezentované na posledních konferencích ASCO se zpravidla netýkaly karcinomu prsu, ale jiných solidních nádorů, jako je maligní melanom, karcinom...
Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5529 Authors: He Huang, Li Yang, Yue...
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial canceR
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5503 Authors: David S. Miller, Giovanni Scambia,...
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
23 septembra, 2020 4:53 pm Leave your thoughtsMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5509 Authors: Lukas Rob, Peter Mallmann, Pawel...